Drug Profile
RO 7123520
Alternative Names: RO-7123520Latest Information Update: 25 Feb 2021
Price :
$50
*
At a glance
- Originator Roche
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 04 Feb 2021 Discontinued - Phase-II for Rheumatoid arthritis (Adjunctive treatment) in USA, Argentina, Austria, Colombia, Germany, Guatemala, Italy, Mexico, Peru, Spain, United Kingdom (IV) (Roche pipeline, February 2021)
- 01 Dec 2016 Phase-II clinical trials in Rheumatoid arthritis (Adjunctive treatment) in USA (IV) (NCT03001219)